In contrast, patients with high tumor B7-H3 had an increased risk for a low 5-year DFS (HR=1.657, 95% CI=1.246-2.203, p=0.001) compared with that of patients with low tumor B7-H3 expression (Table 1). This evidence concerns the gene CD276 and neoplasm.